| Document |
Document Title |
|
WO/2004/050631A1 |
This invention provides a compound of formulae (I) or (II) having the structure or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in tre...
|
|
WO/2004/048340A1 |
The invention relates to sinomenine and compounds thereof and also to compounds of formula (I), wherein R1 represents an alkyl group; R2 represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl;...
|
|
WO/2004/048374A1 |
Compounds represented by Formula (I):or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.
|
|
WO/2004/045562A2 |
This invention features opioid compounds having activity at kappa and mu receptors, methods for preparing the mu/kappa opioids, and methods for the treatment of pain or a dopamine dysregulation disease, such as schizophrenia, attention d...
|
|
WO/2004/043958A1 |
Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the trea...
|
|
WO2003070245B1 |
Mono-ester and asymmetrically substituted diesters of dihydrexidine, dinapsoline and A-86929 and substituted derivatives thereof are described. The novel ester/diester derivatives exhibit improved pharmacokinetic characteristics relative...
|
|
WO/2004/041817A1 |
The invention concerns compounds having an anticancer activity, of formula (I) wherein: R1 represents a hydrogen atom, a (C1-C4)alkyl group or a (CH2)nOH, (CH2)n-O-tetrahydropyran-2-yl, (CH2)nNR'6R'7, (CH2)nCN, (CH2)nCO2(C1-C4)Alk or (CH...
|
|
WO/2004/041163A2 |
The present invention is directed to compounds of the formula I: I(wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, X, Z and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compo...
|
|
WO/2004/037853A2 |
The present invention relates to inhibition of viruses, e.g., HIV using quinolones and compounds related to quinolones. The invention further relates to methods for identifying and using agents, including small molecule chemical composit...
|
|
WO/2004/037792A2 |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as nuclear hormone receptor modulators. The compounds of the instant invention are ligands for nuclear hormone receptors and as such may b...
|
|
WO/2004/037800A1 |
The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
|
WO/2004/031153A2 |
An enantioselective process for preparing intermediates useful in the preparation of the chiral tricyclic compound of formula (I), is disclosed.
|
|
WO/2004/029028A2 |
The invention relates to 9-cyano-substituted perylene-3,4-dicarboxylic acid monoimides (I) where the variables have the following meanings: X = a chemical bond, optionally substituted C1-C30 alkylenes, C5-C8 cycloalkylenes, arylenes, het...
|
|
WO/2004/026859A1 |
Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent ...
|
|
WO/2004/024695A1 |
The invention concerns novel molecules derived from noraporphine, as well as all cosmetic and dermopharmaceutical compositions containing one or several of said derivatives, alone or combined with a plant extract, in particular glaucium ...
|
|
WO/2004/024728A2 |
The invention relates to a compound of formula (I) or a salt thereof: wherein:R1 is C1-4alkyl, C1-3fluoroalkyl, -CH2CH2OH or -CH2CH2CO2C1-2alkyl;R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;R3 is optionally substituted C3-8cycloalk...
|
|
WO/2004/024696A1 |
The invention relates to a novel purification method for the antitumour antibiotic fredericamycin A, said method being characterised by the treatment of fredericamycin A with different solvents. Homopolar solvents can especially be used ...
|
|
WO/2004/024702A1 |
The invention relates to carboxamide compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1, R2, R3, and k have the meanings indicated in claim 1. The invention also relates to methods for producing said ...
|
|
WO/2004/022542A2 |
The invention relates to substituted 1,2,3,4-tetrahydroquinoline derivatives, to methods for the production thereof, to their use for producing medicaments, and to medicaments containing these compounds.
|
|
WO/2004/019944A1 |
Compounds of a certain formula I, in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings indicated in the desription, are novel effective PDE4 inhibitors.
|
|
WO/2004/019945A1 |
Compounds of a formula (I), in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2004/018431A2 |
Compounds of a certain formula (1), in which R1, R2, R3, R31, R4, R5, R51, R6 and R7 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2004/016595A1 |
This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in t...
|
|
WO/2004/014862A1 |
The invention provides compounds of formula (I): wherein: R1-R5, 'a' and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions compris...
|
|
WO/2004/014372A1 |
The present invention relates to acylated, heteroaryl-condensed cycloalkenylamines of the formula I, (I) in which A, R1, R2, R3, R4, R5 and n have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologi...
|
|
WO/2004/013104A1 |
It is intended to provide a nonsteroidal tetrahydroquinoline derivative represented by the following general formula (I), which shows a potent androgen receptor agonism particularly on skeletal muscle tissues and bone tissues without sho...
|
|
WO/2004/013282A2 |
The present invention provides molecular building blocks of rigid bis (amino acids). The molecular building blocks can be linked together through the formation of rigid diketopiperazine rings, to provide the desired three dimensional str...
|
|
WO/2004/009577A1 |
This invention is related to heteroatom containing diamondoids (i.e., 'heterodiamondoids' ) which are compounds having a diamondoid nucleus in which one or more of the diamondoid nucleus carbons has been substitutionally replaced with a ...
|
|
WO/2004/007449A1 |
A process for converting an aryl triflate, heteroaryl triflate, aryl halide or heteroaryl halide to an N-hydroxysuccinimido este is disclosed. The process involves reacting the triflate or halide with carbon monoxide and N-hydroxysuccini...
|
|
WO/2004/006930A1 |
Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
|
|
WO/2004/004714A1 |
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compou...
|
|
WO/2004/004713A1 |
The invention relates to novel fredericamycin derivatives of general formula (Ia) or (Ib), to medicaments containing said derivatives or the salts of the same, and to the use of said fredericamycin derivatives for treating diseases, espe...
|
|
WO/2004/004716A1 |
The present invention concerns novel methods for the synthesis of naphthalimides and mitonafide analogs, as well as salts thereof. Also included are novel compositions, including naphthalimides and naphthalimide salts, analogs thereof, a...
|
|
WO/2004/005295A1 |
The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and thei...
|
|
WO2002080164A9 |
An optical recording medium having at least a recording layer 11 and a light transmitting layer 13 formed on a substrate 10, in which the recording layer 11 is made of an organic material for absorbing an incident light of wavelength of ...
|
|
WO/2004/000816A1 |
A nonsteroidal tetrahydroquinoline derivative represented by the general formula (I): (I) (wherein R1, R2, X, Y, Z, and m are the same as defined in claim 1) or a salt of the derivative. They do not exert excessive activity on the prosta...
|
|
WO/2003/106420A1 |
The present invention concerns compounds of formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatmen...
|
|
WO/2003/099336A1 |
The invention concerns a novel formulation containing: a BIII 890 cyclodextrin complex or one of its phamacologically acceptable salts; a ternary complex consisting of BIII 890 or one of its phamacologically acceptable salts, a cyclodext...
|
|
WO/2003/099280A1 |
The invention relates to a novel formulation containing crobenetine, or one of its pharmaceutically acceptable salts, for parenteral application.
|
|
WO/2003/099819A2 |
The invention relates to compounds of general formula (I) wherein R1 represents H, a (C1-C4) alkyl, -CO(C1-C4)alkyl , (C1-C4)alkyl-phenyl or -CO-phenyl group, whereby phenyl can optionally be substituted, R2 represents H, a halogen atom,...
|
|
WO/2003/097608A2 |
The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations containing the same and methods of use thereof. Uses of the present invention include, but are not limited to, use for the prevention and ...
|
|
WO/2003/097607A1 |
The invention relates to novel substituted tetrahydroisoquinoline derivatives, methods for the production thereof and the use thereof in medicaments, especially as potent PPAR-delta activating compounds for the prophylaxis and/or treatme...
|
|
WO/2003/095427A1 |
A spiro-ring compound represented by the formula (1): (1) wherein the group represented by the formula (2) (2) is any of the formulae (3) to (7): (3) (4) (5) (6) (7) wherein B represents, e.g., a benzene ring optionally substituted by on...
|
|
WO2003028727A9 |
The invention relates to substituted tetrahydroquinoline derivatives of formula (I), wherein A represents a radical (a), (b), (c), (d), (e), (f), (g), (h) or -(CH2)2CH3 and B represents a radical (f) or (h), and to the salts of the same....
|
|
WO/2003/093254A1 |
The invention relates to novel compounds of formula (I), wherein R, R1, R1', X and T have the meaning given in patent claim 1. Said novel compounds are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therap...
|
|
WO/2003/091345A1 |
Production of perylen-3,4:9,10-tetracarboxylic acid diimides of general formula (I), where R = C1-C30 alkyl, the carbon chain of which may be interrupted by one or several -O- groups and/or is substituted with C5-C8 cycloalkyl, which can...
|
|
WO/2003/091220A1 |
The invention described herein are compounds in accordance with formula I:. I Iwherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, R¿2?, R¿8?, R¿9?, n, X, and Z are as defined herein, pharmaceutical compositions containing at least one ...
|
|
WO/2003/089415A1 |
Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is-(CH2)nN+HR3R4 X- or R1 is -(CH2)nN+Hr3r4 X- or -(CH2)nNR3R4 when R2 is -N+HR6R7. R2 is -OR5, halogen, NR6R7, -N+HR6R7 X-, sulphonic acid, nit...
|
|
WO/2003/088963A1 |
This invention provides novel arylindenopyridines of formula: (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate ...
|
|
WO/2003/087060A1 |
The invention relates to novel Fredericamycin derivatives, to medicaments containing these derivatives or salts thereof, and to the use of Fredericamycin derivatives for treating diseases, particularly tumor diseases.
|
